Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com
A00336 | Pages: 260 | Charts: 63 | Tables: 131 |
The global antiemetics market was valued at $2.3 billion in 2021, and is projected to reach $4.1 billion by 2031, growing at a CAGR of 6.1% from 2022 to 2031. The drugs or medications which helps to prevent and treat conditions such as nausea, and vomiting are referred as antiemetic drugs. Emesis can be caused due to various ailments including vertigo and motion sickness. Also chemotherapies are associated with the side effects such as nausea and vomiting which can be treated or prevented with these antiemetics. Furthermore, these antiemetic drugs belongs to different class such as serotonin receptor antagonists, dopamine receptor antagonists, neurokinin receptor antagonists and others and have wide applications in the healthcare sector. These drugs can also be used to treat vomiting caused by several medical conditions, including gastroenteritis, general anesthetics, opioid analgesics, dizziness, pregnancy, food poisoning, emotional stress, and others.
According to Cancer Statistics by the National Cancer Institute, in 2020, an estimated 1,806,590 new cases of cancer were diagnosed in the U.S. and 606,520 people died from the disease, which highlights the higher utilization of the chemotherapy treatment. Chemotherapy-induced nausea and vomiting is the most severe symptoms for cancer patients receiving the chemotherapy which can further lead to metabolic disorders, dehydration, nutritional depletion and esophageal tears, and can affect the quality of life and interfere with treatment schedules. Thus, this highlights the need for the antiemetic treatment for the patient, leading to the expansion of the market. For instance, the most commonly used treatment for chemotherapy-induced nausea and vomiting is a combination of serotonin (5-HT3) receptor antagonists, a steroid (dexamethasone), and a neurokinin-1 (NK1) receptor antagonist (aprepitant).
Furthermore, nausea and vomiting during the pregnancy is a common condition which is known as “morning sickness”. Nausea and vomiting of pregnancy usually doesn't harm the fetus, but it can affect normal everyday activities. American Academy of Family Physicians (AAFP) states that, nausea and vomiting of pregnancy affects nearly 75% of pregnant women and about 1% of women develop hyper-emesis gravidarum, which may result in adverse outcomes for the mother and fetus. In some cases, morning sickness lasts much longer, and antiemetic drugs are extremely helpful in treating such conditions. Thus, this highlights the demand for the antiemetics during the pregnancy propelling the growth of the antiemetics market.
Also the rise in prevalence of the vertigo and vestibular neuritis which causes symptoms as dizziness, balance problems, nausea and vomiting, will contribute to the rise in demand of the antiemetic drugs. Also, the rise in the prevalence of the gastroenteritis, food poisoning, and vomiting and nausea associated diseases boost the antiemetics market growth.
In addition, the primary driving factors for the market growth include the patent expiration of various drugs, launching of more cost-effective generic substitutes, and rise in the investments by the key market players in manufacturing of the antiemetic drug molecules.
Furthermore, less knowledge regarding the appropriate dosage, strength and usage are expected to hamper the market growth. However, increase in healthcare expenditure and rising research and development activities, will provide large antiemetics market opportunity for investment to the market players during the antiemetics market forecast.
[COVIDIMPACTSTATEMENT]
The antiemetics market is segmented on the basis of drug type, application, distribution channel and region. On the basis of drug type, the market is bifurcated into antihistamines, serotonin receptor antagonists, dopamine receptor antagonists, neurokinin receptor antagonists, anticholinergics, and other drug type. On the basis of application, the market is segmented into chemotherapy, post operative surgery, pregnancy and gastroenteritis and other applications. On the basis of distribution channel, the market is categorized into retail pharmacies, hospital pharmacies and online pharmacies. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
Segment Review
By drug type, the serotonin receptor antagonists segment dominated the antiemetics market size in 2021, and is estimated to be the fastest growing segment, with a high CAGR of 7.1% owing to the rise in the demand for Ondansetron and Gravisetron for preventing vomiting and nausea mostly after surgical procedures.
[DRUGTYPEGRAPH]
Depending on the application, the chemotherapy segment dominated the antiemetics market size in 2021, due to the rise in the cancer cases and subsequent rise in the chemotherapies for the treatment whereas the post operative surgery segment is estimated to grow with a CAGR of 6.7% in the forecasted period due rise in the number of surgeries around the globe due to the recent advancements and developments in the surgical procedures which causes the shift of the population towards surgeries as a treatment option.
[APPLICATIONGRAPH]
Depending on distribution channel, the retail pharmacies segment owned the largest share of the antiemetics market share in 2021, whereas the online pharmacies is expected to grow at the highest CAGR of 7.7% during the forecast period due to the rise in the adoption of the smart phones, heavy discounts and offers, doorstep delivery and other advantages of the online pharmacies.
[DISTRIBUTIONCHANNELGRAPH]
Region wise, North America acquired a major antiemetics market share in the year 2021, and registered the growth at a CAGR of 5.1%. However, Asia-Pacific is expected to witness the highest growth rate for the antiemetics market throughout the forecast period with a CAGR of 7.8%. The major factors that drive the growth of the antiemetics market is the elevating healthcare demand for highly potent drug, and adoption of radiation therapy for the cancer treatment. Moreover, availability of excessive raw material in this region and also, the rise in market players investing in research and development are leveraging the antiemetics industry.
[REGIONGRAPH]
Some of the major companies that operate in the global antiemetics industry are Abbott Laboratories, Benuvia Therapeutics Inc., Cipla, Dr. Reddy’s Laboratories Ltd, Eisai Co. Ltd, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Novartis AG, Pfizer In. and Teva Pharmaceuticals among others.
Key Market Segments
Key Market Players